Press Room

10th PBP World Meeting

Start
Monday, April 04, 2016 - 00:00
End
Thursday, April 07, 2016 - 23:00
Location: Glasgow, Scotland
Booth Number: 61

 

HOVIONE'S PRESENTATION

Role of particle engineering in state-of-the-art drug delivery - Most promising technologies and platforms
Speaker: Filipe Gaspar (VP R&D)
Date: Thursday, April 7
Time: 3:40 PM - 4:20 PM
 

HOVIONE'S POSTERS

Development by Design: An approach to spray drying process development
João Vicente

Comparison of spray congealing and hot melt extrusion for the taste masking of bitter drugs
Paula Cordeiro

PLGA Microspheres Produced Using a Membrane Emulsification Process 
Rui Ferreira

Production of nano-solid dispersions using a novel co-precipitation process – benchmarking the in vivo performance with spray dried dispersions
Iris Duarte

 

More details about this event - Exhibition ResearchPharm®, accompanying the 10th PBP World Meeting

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026